Processa Pharmaceuticals, Inc. Impairment of Long-Lived Assets Held-for-use
Processa Pharmaceuticals, Inc. (PCSA) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2018-08-14
- Processa Pharmaceuticals, Inc. impairment of long-lived assets held-for-use for the quarter ending 2018-06-30 was $0.00.
- Processa Pharmaceuticals, Inc. impairment of long-lived assets held-for-use for fiscal 2017 was $15.33K.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|
| 2018-06-30 | $0.00 10-Q · filed 2018-08-14 | $0.00 10-Q · filed 2018-08-14 | |
| 2017-12-31 | $15.33K 10-K · filed 2018-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |